45 Results

People

  1. Slovin
    Slovin
  2. Scher
    Scher
  3. Morris
    Morris
  4. Kelly
    Kelly
  5. Heller
    Heller
  6. Schwartz
    Schwartz
  7. Smart-Curley
    Smart-Curley
  8. Solit
    Solit
  9. Larson
    Larson
  10. De La Cruz
    De La Cruz

Groups

  1. Department of Medicine (45)
  2. Genitourinary Oncology Service (45)
  3. Hematologic Malignancies, Division of (45)
  4. Solid Tumor Oncology Division (45)
  5. GSK Faculty (17)
  6. Nursing (14)
  7. Molecular Pharmacology and Chemistry Program Faculty (13)
  8. Radiology, Department of (13)
  9. Sloan Kettering Institute Faculty (13)
  10. Epidemiology and Biostatistics (12)
  1. "adult"
  2. "Susan Slovin"
  3. "Solid Tumor Oncology Division"
  4. "Genitourinary Oncology Service"
Formats
  1. Journal Article (45)
Groups
  1. Department of Medicine (45)
  2. Genitourinary Oncology Service (45)
  3. Hematologic Malignancies, Division of (45)
  4. Solid Tumor Oncology Division (45)
  5. GSK Faculty (17)
  6. Nursing (14)

More Groups

People
  1. Susan Slovin (45)
  2. Howard Scher (35)
  3. Michael Morris (25)
  4. William Kelly (14)
  5. Glenn Heller (10)
  6. Lawrence Schwartz (10)

More People

Years
  1. 2023 (3)
  2. 2020 (1)
  3. 2019 (1)
  4. 2017 (1)
  5. 2014 (2)
  6. 2013 (2)

More Years

Publications
  1. Clinical Cancer Research (9)
  2. Cancer (7)
  3. Journal of Clinical Oncology (3)
  4. Annals of Oncology (2)
  5. Cancer Immunology, Immunotherapy (2)
  6. European Urology (2)

More Publications

Publishers
  1. American Association for Cancer Research (9)
  2. Wiley Blackwell (7)
  3. Elsevier Science, Inc. (6)
  4. American Society of Clinical Oncology (5)
  5. Springer (4)
  6. Elsevier Inc. (3)

More Publishers

Results (45)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Evaluating immune-related adverse events using PRO-CTCAE in a phase II study of ipilimumab for hormone-sensitive prostate cancer
    Journal Article

    Vargas P. de Almeida, D.; Anderson, J. M.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Abida, W.; Cohn, E. D.; Baser, R. E.; Scher, H. I.; Autio, K. A.
    Journal of Immunotherapy and Precision Oncology (2023)

    Fulltext@MSK | Save
  • Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials
    Journal Article

    Cornetta, K.; Yao, J.; House, K.; Duffy, L.; Adusumilli, P. S.; Beyer, R.; Booth, C.; Brenner, M.; Curran, K.; Grilley, B.; more...
    Molecular Therapy (2023)

    Fulltext@MSK | Save
  • Gene-based confirmatory germline testing following tumor-only sequencing of prostate cancer
    Journal Article

    Truong, H.; Breen, K.; Nandakumar, S.; Sjoberg, D. D.; Kemel, Y.; Mehta, N.; Lenis, A. T.; Reisz, P. A.; Carruthers, J.; Benfante, N.; more...
    European Urology (2023)

    Fulltext@MSK | Save
  • Platinum-based chemotherapy in metastatic prostate cancer with DNA repair gene alterations
    Journal Article

    Mota, J. M.; Barnett, E.; Nauseef, J. T.; Nguyen, B.; Stopsack, K. H.; Wibmer, A.; Flynn, J. R.; Heller, G.; Danila, D. C.; Rathkopf, D.; more...
    JCO Precision Oncology (2020)

    Fulltext@MSK | Save
  • A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer
    Journal Article

    McHugh, D.; Eisenberger, M.; Heath, E. I.; Bruce, J.; Danila, D. C.; Rathkopf, D. E.; Feldman, J.; Slovin, S. F.; Anand, B.; Chu, R.; more...
    Investigational New Drugs (2019)

    Fulltext@MSK | Save
  • Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making
    Journal Article

    Abida, W.; Armenia, J.; Gopalan, A.; Brennan, R.; Walsh, M.; Barron, D.; Danila, D.; Rathkopf, D.; Morris, M.; Slovin, S.; more...
    JCO Precision Oncology (2017)

    Fulltext@MSK | Save
  • Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer
    Journal Article

    Hussain, M.; Carducci, M. A.; Slovin, S.; Cetnar, J.; Qian, J.; McKeegan, E. M.; Refici-Buhr, M.; Chyla, B.; Shepherd, S. P.; Giranda, V. L.; more...
    Investigational New Drugs (2014)

    Fulltext@MSK | Save
  • Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody
    Journal Article

    Iwama, S.; De Remigis, A.; Callahan, M. K.; Slovin, S. F.; Wolchok, J. D.; Caturegli, P.
    Science Translational Medicine (2014)

    Fulltext@MSK | Save
  • Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: Results from an open-label, multicenter phase i/ii study
    Journal Article

    Slovin, S. F.; Higano, C. S.; Hamid, O.; Tejwani, S.; Harzstark, A.; Alumkal, J. J.; Scher, H. I.; Chin, K.; Gagnier, P.; McHenry, M. B.; more...
    Annals of Oncology (2013)

    Fulltext@MSK | Save
  • Repetitively dosed docetaxel and 153samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer
    Journal Article

    Autio, K. A.; Pandit-Taskar, N.; Carrasquillo, J. A.; Stephenson, R. D.; Slovin, S. F.; Rathkopf, D. E.; Hong, C.; Heller, G.; Scher, H. I.; Larson, S. M.; more...
    Cancer (2013)

    Fulltext@MSK | Save